||
新试验探索BAFF CAR -T细胞治疗复发性骨髓瘤
https://www.ebiotrade.com/newsf/2024-8/20240816070734073.htm
(61)
(51)
(23)
(11)
(4)
(4)
(4)
(4)
(3)
(3)
http://www.pubmedplus.cn/P/SearchQuickResult?wd=28e1d45d-8d42-41cb-93f4-42fa5da10d9b
Winship Cancer Institute, Emory University, Atlanta, Georgia.
Blood Cancer Discov (P 2643-3249 E 2643-3230) H指数:0 2022 年 3 卷 6 期 490-501 页
PMID:36026513 相似文献
http://www.pubmedplus.cn/P/SearchQuickResult?wd=7748cfe3-63ef-4eac-9cbc-b08ebf67495c
01. | Humans | 93 篇 | 85.321% |
02. | Multiple Myeloma | 91 篇 | 83.486% |
03. | B-Cell Maturation Antigen | 80 篇 | 73.394% |
04. | Receptors, Chimeric Antigen | 80 篇 | 73.394% |
05. | Immunotherapy, Adoptive | 59 篇 | 54.128% |
06. | T-Lymphocytes | 49 篇 | 44.954% |
07. | Animals | 29 篇 | 26.606% |
08. | Mice | 24 篇 | 22.018% |
09. | Male | 22 篇 | 20.183% |
10. | Neoplasm Recurrence, Local | 22 篇 | 20.183% |
https://pubmed.ncbi.nlm.nih.gov/36026513/
Editorial
Blood Cancer Discov
. 2022 Nov 2;3(6):490-501.
doi: 10.1158/2643-3230.BCD-22-0018.
Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in MyelomaAffiliations expand
PMID: 36026513
PMCID: PMC9627239
Archiver|手机版|科学网 ( 京ICP备07017567号-12 )
GMT+8, 2024-8-20 03:19
Powered by ScienceNet.cn
Copyright © 2007- 中国科学报社